"Over the next quarter the company will be firmly focused on optimising the launch of the Turbine nasal dilator and supporting the growth of the awareness and sales of the product. In the lead-up to our launch, we will continue to keep investors informed.
Key upcoming events include: § Microcap Investment conference (October 23): http://tinyurl.com/lfy775w; § Ausbiotech Invest conference (October 29): http://ausbiotechinvest.com; § Rhinomed Limited AGM, Keith Miller Room at the Melbourne Cricket Ground (November 12); § Turbine launch mid November"
Also I agree with your post Steini. Gave you a thumbs up from me! I reckon those targets could be conservative though IF the sales figures are really positive. Remember CGP heads price almost did 4 baggers in just over ONE MONTH from June to July. Althought it was from fairly low base of 1.5c, I think we could do a lot better than 10c on heads in short to medium term imo.
17 june CGP was at low of 1.5c per share 22 July high of 5.7c People this is 380% in just over one (1) month!! That was also on no turbine launch, no roadshows, no presentations at investor biotech conferences during 17 june to 22 July….
Between 17 June and 22 July 2013 these were the only announcements released. 4 in total: • Securities trading policy ann 20 June • Appendix 3B and Section 708A Notice 1 July • Price query and response 5 July • Appendix 3B and Section 708A Notice 9 July
None of these were flagged price sensitive except the 5 July which was just a price query announcement probably just trying to slow it down which also didn’t work. The two announcements prior to this time that would’ve likely created additional interest for us amongst others (and were both notably were both flagged as ‘price sensitive’) were announcements from 5 June (‘Results from BreatheAssist Elite Athletes User Trial’) and from 6 May (‘Consegna advances commercialisation of BreatheAssist Sport’).
Liked reading all of the FAQ's also. Esp these ones:
Q You are targeting elite athletes. Where will the growth come from? A Elite athletes are well known as early adopters of technology that provides them with an edge, technology that has the potential to assist them to improve their performance. There are many examples of where this is the case and it is certainly something we have confirmed with our customer and user research. What is equally important is that elite athletes are also a critically important reference group for a much larger mass market – the amateur sport and exercise participant. We anticipate significant growth with come from this market once we have established ourselves with elite athletes.
Q You claim nasal breathing provides real benefits, how do you know? A Nasal breathing has long been linked to health benefits. A quick search on the internet will turn up a number of links and sites that confirm this. Our device optimises breathing through the nose! Check out some of these articles: http://tinyurl.com/ko48tq9 http://tinyurl.com/m5chk57 http://tinyurl.com/mrf3ey6 http://tinyurl.com/cjpcek
Q What are your expectations over the next six months? A Our objective has always been to launch the Turbine™ this year. We will deliver on this promise. We have a naturally conservative approach when it comes to budgeting and our lean management structure reflects this. We will ensure we give the Turbine the support it needs without putting the company into any position of risk financially. We will be focusing all our efforts to get Rhinomed to a cash flow breakeven position as quickly as we can, and then into a position of significant strength that allows us to invest in the growth of the company
CGP Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
